(Q31055878)

28 June 2017

title

Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors (English)

1 reference

28 June 2017

Tsekes G

1

1 reference

28 June 2017

Chrysos G

2

1 reference

28 June 2017

Douskas G

3

1 reference

28 June 2017

Paraskeva D

4

1 reference

28 June 2017

Mangafas N

5

1 reference

28 June 2017

Giannakopoulos D

6

1 reference

28 June 2017

Papanikolaou M

7

1 reference

28 June 2017

Georgiou E

8

1 reference

28 June 2017

Lazanas MC

9

1 reference

28 June 2017

publication date

1 April 2002

1 reference

28 June 2017

1 reference

28 June 2017

volume

3

1 reference

28 June 2017

issue

2

1 reference

28 June 2017

page(s)

85-90

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Lipodystrophy in patients naive to HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Validation of a dual energy X-ray absorptiometer: measurement of bone mass and soft tissue composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Fat distribution and metabolic changes in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Visceral abdominal-fat accumulation associated with use of indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

Assessment of whole-body composition with dual-energy x-ray absorptiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00105.X

10.1046/J.1468-1293.2002.00105.X

21 January 2018

Identifiers

DOI

1 reference

28 June 2017

1 reference